Abstract-Lack of understanding of the early mechanisms of aortic valve stenosis and calcification hinders the development of diagnostic and therapeutic intervention strategies. Inflammation is a known component of early aortic valve disease and can induce mesenchymal transformation in a subset of aortic valve endothelial cells. Here we present a three-dimensional culture system that allows transforming and non-transforming cells to be independently isolated and analyzed. We have used the system to identify and characterize the dynamic invasion and phenotypic transition of two distinct subsets of endothelial cells: those that invade and transform under TNFa treatment, and those that resist mesenchymal transformation and remain endothelial. We determine that non-transformed cells maintain control levels of endothelial genes VE-cadherin and eNOS, while transformed cells lose these endothelial characteristics and upregulate a-smooth muscle actin. Both subsets of cells have an inflammatory phenotype marked by increased ICAM-1, but transformed cells have increased MMP-9, Notch1, TGF-b, and BMP-4, while non-transformed cells do not. Transformed cells also have distinct effects on alignment of collagen fibers as they invade the hydrogel system, which is not found in control endothelial or interstitial valve cells. Understanding the role of transforming and non-transforming endothelial cells in valve disease will provide an important pathological link between early inflammation and later stages of disease. Discovery of the molecular signature of transformation-resistant endothelial cells could inform development of treatment strategies that promote survival of the valve endothelium.
INTRODUCTION
Aortic valve disease (AVD) affects 2.8% of Americans over 75 years of age.
14 Approximately 40% of severe cases undergo cardiothoracic surgery 14 due to the lack of effective pharmaceutical treatments for AVD. Without surgical intervention, the majority of affected patients will die within 1 year of diagnosis. 29 Inflammation is a hallmark of early AVD 18 and new molecular imaging techniques have identified endothelial activation and damage to be a key early response. 1 However, limited understanding of the role of inflamed endothelial cells in AVD prohibits development of clinically useful strategies targeting valve endothelial pathobiology.
Recent studies suggest that valve endothelial function is a key regulator of early AVD via recruitment of immune cells, 14 dysregulation of protective nitric oxide signaling, 27 phenotypic plasticity, 32 and through expression of pro-calcific proteins. 28 We recently showed that inflammatory cytokine TNFa drives an endothelial to mesenchymal transition (EndMT) in a subset (5-10%) of adult valve endothelial cells (VEC). 24 Adult VEC EndMT also occurs in response to pathological levels of mechanical strain, 3 elevated TGF-b signaling, 26 or activation of cell-signaling ligand Notch1. 33 These studies used clonal isolations of VECs and found, similar to inflammatory-EndMT, that mesenchymal transformation occurred only in a fraction of VEC. This subset of VEC that is uniquely able to transform under EndMT stimuli may have important roles in later AVD. A subset of VEC clonally isolated from MV can undergo EndMT and exhibits the capacity for osteogenic differentiation, suggesting their potentially unique participation in advanced mitral valve disease. 4, 32 It is unknown how EndMT-VEC in the aortic valve participate in advanced AVD. In addition, the subset of VEC that do not transform may possess unique phenotypic signatures which promote resistance to mesenchymal transformation and potentially an ability to protect against disruption of the protective endothelial layer. These intriguing questions have not been examined due to the difficulty of separating transforming from nontransforming cells during EndMT. Studies are needed which are able to characterize transforming and nontransforming VEC in a controlled manner, elucidating the three-dimensional and time-dependent EndMT response of VEC to pathological conditions.
Here we have designed a system consisting of a porcine aortic VEC cultured on a porous membrane combined with a collagen hydrogel. Endothelial cells treated with EndMT stimuli can invade, interact with a collagen gel matrix, and be separately isolated and studied from non-transformed endothelial cells. Aortic VEC can maintain an endothelial phenotype on the membrane for up to 6 days, or undergo a full mesenchymal transformation by invading the underlying matrix. We used the system to characterize timedependent dynamics of the TNFa-EndMT process, involving distinct stages of endothelial or myofibroblastic protein expression. We identified a unique subpopulation of non-transforming cells that maintained endothelial characteristics under TNFa, suggesting resistance to EndMT. We also isolated a subset of transforming endothelial cells, in which we quantified the expression of genes related to AVD, including MMP9, TGF-b1, Notch1, and BMP-4. Finally, we examined the effects of the transforming cells on their surrounding collagen matrix, as an initial investigation of the ability of these cells to contribute to valvular matrix remodeling. These results are an important step forward in characterizing VEC transformed by inflammatory EndMT and understanding their role in the progression of AVD. Furthermore, the ability to segregate and study a population of non-transforming VEC which are resistant to inflammatory EndMT establishes a foundation for identifying molecular mechanisms which may provide protection against mesenchymal transformation.
METHODS AND MATERIALS

Cell Isolation and Culture
Porcine aortic valve endothelial cells (PAVEC) and porcine valve interstitial cells (PAVIC) were isolated as described previously 16 from valves donated by Shirk Meats of Dundee, NY. PAVEC were grown in flasks coated with 50 lg/mL rat-tail collagen I (BD Biosciences, San Jose, CA) at 37°C and 5% CO 2 in D-MEM (Invitrogen, Grand Island, NY) supplemented with 10% FBS (Invitrogen, Grand Island, NY), 1% penicillin-streptomycin (Invitrogen, Grand Island, NY), and 50 U/mL heparin (Sigma-Aldrich, St Louis, MO).
Cells were passaged 1:3 at confluency using 0.25% trypsin-EDTA (Invitrogen,) and media was changed every 48 h. PAVIC were cultured identically, but without collagen flask coating or heparin in the culture media. Purity of endothelial population was monitored via quantitative real-time PCR, western blot, and immunofluorescent assessment. Only cultures with consistent CD31 and VE-cadherin expression, cobblestone morphology, and non-detectable aSMA expression were used. aSMA levels were measured using realtime PCR (>37 cycle threshold), western blot, and immunofluorescence. PAVEC and PAVIC cultures were used between passage four and six.
3-D Culture System
Tissue-culture treated, sterile, polycarbonate membrane inserts (Corning, Inc., Corning, NY) were obtained in 3 and 8 lm pore sizes and machined to a depth of 0.5 mm. Membranes were coated in collagen I, 50 lg/mL (BD Biosciences, San Jose, CA) and filled with collagen gel composed of 10% FBS (Gemini Biosciences, West Sacramento, CA), D-MEM, and 2 mg/mL collagen type I (BD Biosciences, San Jose, CA), adjusted to a pH of 7.2. After 1 h incubation at 37°C, PAVEC were seeded at 100,000 cells/cm 2 and allowed to adhere overnight. Membrane system was then carefully submerged in PAVEC culture media, which served as the control media for all experimental groups. For experiments, 30 ng/mL TNFa (Sigma Aldrich, St Louis, MO) was added to control media. The membrane system was completely submerged in either control or +TNFa media for 2-6 days (Fig. 1) . PAVIC gels were made as described previously. 6 Western Blot PAVEC were grown to 70% confluency in a 75 cm 2 tissue culture flasks, then lysed directly on the plate using RIPA buffer supplemented with 25 mM NaF, 1 mM NaVO 4 , and 0.5% Protease inhibitor cocktail (Sigma), incubated for 15 min at RT, scraped and homogenized by pipetting up and down, and centrifuged at 15,000 rpm for 10 min. 10 lg of protein was loaded into a 4-15% gradient gel (Bio-Rad, Hercules, CA) with 29 Laemmli buffer (Bio-Rad, Hercules, CA) at 1:1 ratio and run for 1 h at 120 V in 25 mM tris, 0.2 M glycine, 1% SDS running buffer. Western blot transfer to nitrocellulose membrane (Thermo Scientific, Rockford, IL) was performed at 400 mA for 1 h in 25 mM Tris (Bio-Rad, Hercules, CA) methanol transfer buffer. After rinsing in PBS 0.1% Tween-20, membrane was blocked for 1 h in Odyssey Blocking Buffer (Li-Cor, Lincoln, NE) at RT. Mouse anti-human VE-cadherin (Abcam, Cambridge, MA) (1:1000), rabbit anti-human alpha-smooth muscle actin (Abcam, Cambridge, MA) (1:1000), and mouse anti-human GAPDH (Invitrogen, Grand Island, NY) (1:10,000) were used in Odyssey blocking buffer + 0.1% Tween-20 to detect protein expression. The membrane was washed 49 in PBS + 0.1% tween-20, 19 in PBS, and incubated overnight at 4°C with gentle agitation. The same washes were then performed and the membrane was incubated in Odyssey blocking buffer + 0.1% Tween-20 + 0.2% SDS with 1:20,000 anti-mouse and anti-goat secondary antibodies (Li-Cor IRDye, Lincoln, NE). Blots were imaged using the Odyssey Infrared system (Li-Cor, Lincoln, NE). After purity of endothelial population was confirmed, PAVEC from the same cell isolation were used in membrane system experiments.
Immunofluorescence
The intact membrane system (with cells on membrane and/or within collagen gel) was rinsed twice in PBS and fixed in 4% paraformaldehyde for 1 h at 37°C. Samples were rinsed three times on a rocker with PBS for 15 min each, permeabilized with 0.2% Triton-X (VWR International, West Chester, PA) for 10 min on rocker, and blocked in 10% goat serum for 1 h at 37°C. Samples were rinsed briefly in PBS and primary antibodies were added: mouse anti-pig CD31 (AbD Serotec, Kidlington, UK, 1:100), rabbit antihuman aSMA (Abcam, Cambridge, MA, 1:100), rabbit anti-human Snai1 (Santa Cruz Biotechnology, Dallas, TX, 1:50) and AlexaFluor 488 Ò phalloidin (Invitrogen, Grand Island, NY, 1:100). Samples were incubated overnight at 4°C, rinsed three times in PBS on rocker for 15 min each, and species-specific secondary antibodies raised in goat conjugated to Alexa Fluor Ò 488 or 568 fluorophores (Invitrogen, Grand Island, NY, 1:100) were added. Samples were incubated for 2 h at room temperature, rinsed, then incubated for an additional 30 min with Draq5 nuclear stain (Enzo Life Sciences AG, Lausen, Switzerland, 1:1000). Samples were rinsed thoroughly in PBS three times on rocker for 15 min each, then imaged using a Zeiss 710 (Thornwood, NY) laser scanning confocal microscope. Confocal reflectance was used to image collagen fibers within the gel, collected as a successive stack but with identical image volume as the immunofluorescence imaging.
Quantitative Real-Time Polymerase Chain Reaction
To separately isolate PAVEC remaining on the membrane from PAVEC within the collagen gel, the collagen gel was first removed from the membrane system and vortexed in RLT buffer plus 1% betamercaptoethanol (Qiagen, Valencia, CA) until dissolved and frozen at 280°C. The membrane was then submerged in 0.25% trypsin-EDTA for 5 min at 37°C. Three times the volume of media was added to the membrane unit to stop the trypsin reaction and any remaining cells were scraped gently from the membrane. The cell, trypsin, and media solution was then spun down at 1000 rpm for 5 min at room temperature. The cell pellet was rinsed in 19 PBS, resuspended in RLT buffer plus 1% beta-mercaptoethanol, and frozen at 280°C.
Total RNA was extracted using a RNeasy total RNA purification kit (Qiagen, Valencia, CA) and RNA was reverse transcribed to cDNA using the iScript TM cDNA synthesis kit (Bio-Rad, Hercules, CA). Quantitative real-time PCR was performed on all samples using SsoAdvanced SYBR green super mix (Bio-Rad, Hercules, CA), and a CFX96 or MiniOpticon Real-Time PCR Detection System (Bio-Rad, Hercules, CA) ( Table 1) .
Data Analysis
All experiments were performed with n ‡ 3. Data is expressed as mean ± standard error of the mean (SEM). All comparisons between two groups were made using two-tailed, unpaired t-tests assuming unequal variance. Comparisons between multiple groups were made using ANOVA. Differences between means were considered significant when p < 0.05.
RESULTS
Culture System Supports Maintenance of PAVEC Monolayers and Collagen Invasion
Pure populations of healthy PAVEC, with confirmed expression of VE-cadherin and no aSMA (Fig. 2a) , were cultured for up to 6 days on either the 3 lm membrane (Fig. 2b) or the 8 lm membrane (Fig. 2c) . PAVEC cultured on membranes form confluent monolayers with strong CD31 expression and cobblestone morphology (Fig. 2d) . PAVEC have no aSMA expression and do not invade the underlying gel (Figs. 2e and 2f). When treated with TNFa, a subset of PAVEC passes through the membrane and invades the underlying gel (Fig. 2g) .
We then used confocal microscopy to image PA-VEC undergoing EndMT on the membrane system ( Fig. 3 ). Viewed from above, en face to the membrane surface, we observed heterogeneity in the expression of aSMA within PAVEC remaining on the membrane. All PAVEC expressed CD31 (red), but only a subset had increased aSMA expression (green, arrows) (Fig. 3a) . Using a three-dimensional reconstruction to view the system from the side, we imaged individual PAVEC passing through a membrane pore ( Fig. 3a,  arrowheads; Fig. 3b , dashed lines). Invading cells had increased aSMA (green) and decreased CD31 (red, arrow), consistent with an EndMT phenotypic shift. When the same cell field was reconstructed as a threedimensional image (Fig. 3c ), invading cells were seen to be protruding into the collagen gel (arrow). PAVEC were also observed to be invading the gel (asterisks). A subset of PAVEC remained on the surface of the membrane (Figs. 3b and 3c ). These cells were variably distributed across the membrane pores (Fig. 3a) , suggesting that proximity to a pore was not the primary factor in determining whether a cell would invade. This variation in invasion suggested that the initial population of VEC possessed variation in ability or propensity to undergo EndMT with TNFa stimulus.
Time-Dependent Dynamics of TNFa-EndMT
Using the membrane system to separate transformed PAVEC (T-VEC) from non-transformed PA-VEC (NT-VEC), we characterized the EndMT phenotype of both cell populations after 2, 4, or 6 days of TNFa treatment. All treatment groups (T-VEC and NT-VEC) were compared to PAVEC cultured on the membrane for equal lengths of time in control media. There was no invasion in control groups. Using the 3 lm pore membrane, we found that endothelial cellcell adhesion protein VE-cadherin was increased in NT-VEC at day 2 (2.08 ± 0.19 fold, p = 0.01) and remained similar to control levels through day 4 (0.68 ± 0.1 fold, p = 0.23) and day 6 (0.82 ± 0.1 fold, p = 0.32) (Fig. 4a) . The initial increase in VE-cadherin expression may be due to the re-organization of cellcell contacts as subsets of PAVEC invade and NT-VEC form new attachments. The gene encoding transcription factor Snail (Snai1), which is associated with EMT, 7 was increased in both NT-VEC (7.6 ± 2.8 fold, p = 0.008) and T-VEC (4.4 ± 0.2 fold, p = 0.05) after 18S  TAGAGGGACAAGTGGCGT  AATGGGGTTCAACGGGTT  ACTA2  CAGCCAGGATGTGTGAAGAA  TCACCCCCTGATGTCTAGGA  CD31  ATCTGCATCTCGTGGGAAGT  GAGCTGAAGTGTCAGCAGGA  Snai1  GCCCAACTACAGCGAGCTAC  CCAGGAGAGACTCCCAGATG  VE-cadherin  CGTGGTGGAAACACAAGATG  TGTGTACCTGGTCTGGGTGA  MMP-9  TGGGAGTACTGGCGACTCT  ACTTGGCGTCCAGAGAAGAA  TGF-b1  TTTCTGGTGGGGAGACAGAC  CTCCCCTAGGCTGCTTTCTT  Notch1  TGGATGGCATCAATTCCTTT  GGGCAGGTACACTTGTAGGC  BMP-4  AAAAAGTCGCCGAGATTCAG  CCGCATGTAATCTGGGATG  ICAM-1  AAAGGAGGCTCCATGAAGGT  TGCCATCGTTTTCCACATTA  VCAM-1  TTGTTGCCTCGTCACACAGC  CAATCTGCGCAATCATTTTG  NOS3 TGCATGACATTGAGAGCAAAGG GATGGTCGAGTTGGGAGCAT 2 days of treatment, when compared to PAVEC treated with control media (Fig. 4b) . At 4 days, Snai1 was decreased in NT-VEC (0.36 ± 0.04 fold, p = 0.09) and increased in T-VEC (7.81 ± 1.5 fold, p = 0.02). At 6 days, Snai1 was decreased in NT-VEC (0.13 ± 0.01 fold) and increased in T-VEC (2.4 ± 0.9 fold, p = 0.02). NT-VEC maintained low expression of aSMA through day 2 (1.05 ± 0.4, p = 0.3), day 4 (0.23 ± 0.09, p = 0.02), and day 6 (not detectable). However, T-VEC increased in aSMA over time, through day 2 (3.1 ± 1.0 fold, p = 0.1), day 4 (2.13 ± 0.2 fold, p = 0.1), and day 6 (15.6 ± 1.1 fold, p = 0.006) (Fig. 4c) .
To understand the effects of pore size on the time dynamics of PAVEC TNFa-EndMT, we repeated the EndMT time-course experiments with an 8 lm poresize membrane. We found that the stages of EndMT were the same with the larger pores, but occurred more rapidly. NT-VEC had decreased VE-cadherin at day 2 (0.18 ± 0.01 fold, p = 0.0001) which could be due to re-organization of cell-cell contacts during the first phase of invasion. NT-VEC had VE-cadherin levels similar to control samples at day 3 (0.8 ± 0.2 fold, p = 0.3) and day 4 (0.8 ± 0.06 fold, p = 0.07). T-VEC had increased expression of VE-cadherin at day 3 (5.0 ± 1.9 fold, p = 0.4), suggesting that transformed cells maintain some of their endothelial characteristics as they invade. T-VEC had decreased VE-cadherin by day 4 (0.1 ± 0.1 fold, p > 10 26 ), indicating progressive mesenchymal transformation (Fig. 4d) . NT-VEC had levels of Snai1 lower than control at day 2 (0.5 ± 0.02 fold, p = 0.02), and similar to control at day 3 (2.0 ± 0.5 fold, p = 0.15), and day 4 (1.1 ± 0.01 fold, p = 0.3). Snai1 expression was increased in T-VEC at day 3 (22.5 ± 3.2 fold, p < 10
23
) and returned to control levels by day 4 (Fig. 5e) . Absence of an upregulation in Snai1 in NT-VEC could be attributed to the larger pore size, which allows EndMT cells to undergo full mesenchymal transformation more rapidly. Thus, Snai1 increase may occur prior to the 2-day time-point. NT-VEC had aSMA levels similar to control. T-VEC had low levels of aSMA at day 2 (0.01 ± 0.003 fold, p = 0.4) and day 3 (0.8 ± 0.5 fold, p = 0.03). T-VEC had increased aSMA at 4 days after treatment (14.8 ± 2.5 fold, p < 10 24 ), rather than the 6 days required for increased aSMA in the 3 lm system (Fig. 4f) . These results suggest that a larger pore size does not affect the mechanism of progression of TNFa-EndMT in PAVEC, but allows the process to occur more rapidly.
EndMT Protein Expression in Transforming Valve
Endothelial Cells
To confirm the changes in gene expression and time dynamics of EndMT observed in the membrane system, we analyzed expression and localization of CD31, Snail, and aSMA proteins in NT-VEC and T-VEC across 2, 4, and 6 days of treatment on the 3 lm pore membrane. NT-VEC had initial increases in Snail expression and nuclear localization at day 2, which was decreased at days 4 and 6. NT-VEC consistently expressed membranous CD31, an endothelial marker (Figs. 5a-5c ). T-VEC co-expressed CD31 and aSMA at day 2, with increasing aSMA at days 4 and 6 (Figs. 5d-5f). CD31 expression decreased at day 6, but was still observable at some cell-cell junctions (Fig. 5f , arrows).
Characterization of Transformed Valve Endothelial Cells
We then used the membrane system to characterize expression of genes related to valve disease in both NT-VEC and T-VEC. We compared NT-VEC and T-VEC with untreated VEC controls, with PAVIC embedded in the collagen gel with no treatment, and with embedded VIC treated with TNFa. Control VEC (0.05 ± 0.02 fold, p = 0.03) and NT-VEC (not detected) had very low levels of MMP-9 compared to control VIC. T-VEC, however, had very high levels of MMP-9 (250 ± 43 fold, p = 0.0002) compared to control VIC (Fig. 6a) . VIC + TNFa also had elevated MMP-9 (3.0 ± 0.24 fold, p = 0.043) compared to control VIC. TGF-b1 was increased in T-VEC (6.9 ± 1.5 fold, p = 0.009) and VIC + TNFa (6.1 ± 1.0 fold, p = 0.002) compared to control VIC (Fig. 6b) . Notch1 was increased in control VEC (3.78 ± 0.24 fold, p = 0.002), T-VEC (75.8 ± 4.7 fold, p = 0.003), and VIC + TNFa (4.1 ± 0.4 fold, p = 0.0009) compared to control VIC. NT-VEC (1.39 ± 0.04 fold, p = 0.09) had similar levels of Notch1 as control VIC (Fig. 6c) . BMP-4 was increased in control VEC (6.98 ± 0.6 fold, p = 0.002), T-VEC (38.84 ± 0.4 fold, p = 0.006), and VIC + TNFa (3.63 ± 1.1 fold, p = 0.05) compared to control VIC (Fig. 6d) . NT-VEC (0.78 ± 0.13, p = 0.34) had similar levels of BMP-4 as control VIC.
We also examined expression of inflammatory adhesion molecules ICAM-1 and VCAM-1 in all groups compared to control VEC. ICAM-1 was increased in NT-VEC (2.0 ± 0.2 fold, p = 0.009), T-VEC (5.05 ± 1.9 fold, p = 0.05), and VIC + TNFa ( Fig. 6e) . Control VIC had similar levels of ICAM-1 as control VEC (0.97 ± 0.04 fold, p = 0.79). VCAM-1 was increased in NT-VEC (1.6 ± 0.1 fold, p = 0.009) and VIC + TNFa (1.4 ± 0.2 fold, p = 0.047) compared to control VEC. Control VIC had similar levels of VCAM-1 as control VEC (1.1 ± 0.12, p = 0.49) (Fig. 6f) . Finally, we quantified levels of the gene encoding endothelial nitric oxide synthase (eNOS), NOS3, across groups compared to control VEC as a further examination of endothelial phenotype. NT-VEC had similar levels of NOS3 as control VEC (0.9 ± 0.09 fold, p = 0.42), while T-VEC (0.23 ± 0.4, p = 0.16), control VIC (0.09 ± 0.01 fold, p < 10
23
), and VIC + TNFa (0.27 ± 0.04 fold, p = 10 23 ) had decreased levels of NOS3 compared to control VEC (Fig. 6g) .
Transformed Valve Endothelial Cells Rearrange Collagen Extracellular Matrix
We further characterized the phenotype of T-VEC by assessing the arrangement of collagen fibers in gels containing T-VEC vs. gels with control VEC or VIC. Control VEC cultured directly on collagen gels did not affect the arrangement of collagen fibers (Fig. 7a) . In contrast, collagen fibers in the region of T-VEC were elongated and aligned with the long axes of the transformed cells (Fig. 7b, dashed double arrows) .
VIC embedded in an identical collagen gel did not affect collagen fiber alignment (Fig. 7c) . Similar to the control VEC condition, the fibers in the VIC gels were short and randomly oriented. The ability of T-VEC to interact with the collagen gel suggests that T-VEC may be able to play a role in affecting the changes in extracellular matrix seen in AVD. 10 
DISCUSSION
A greater understanding of the heterogeneity, timedependence, and pathogenic role of VECs undergoing mesenchymal transformation is necessary to connect EndMT pathophysiology with the treatment of AVD. Here we have utilized a novel in vitro system to characterize TNFa-induced EndMT in aortic VECs. We identified a population of non-transforming aortic VECs that resists TNFa-EndMT and retains an endothelial phenotype, and a population of transformed cells that acquires a mesenchymal and prodisease phenotype with TNFa treatment.
Previous studies have employed clonal isolation systems to study and assess the ability of certain subgroups of VEC to undergo EndMT. 3, 4, 26, 32, 33 The use of primary cells cultured together on the membrane system described here is advantageous because it allows cell-cell communication between transforming (f) VCAM-1 levels were similar in control VEC and control VIC. NT-VEC and VIC + TNFa had elevated VCAM-1 levels and T-VEC had decreased VCAM-1 compared to control VEC. (g) NOS3 levels were similar in control VEC and NT-VEC. NOS3 levels were lower in T-VEC, control VIC, and VIC + TNFa compared to control VEC. All experiments performed with n > 3. Errors bars indicate SEM. * indicates p < 0.05 vs. control; ** indicates p < 0.05 vs. indicated group, according to ANOVA followed by Student's t test. VCaM-1 indicates vascular cell adhesion protein 1; ICAM-1, intercellular adhesion molecule 1.
commissures which have shown increased inflammation in early disease, 1 or a side-specific isolation. These further studies would capitalize on the ability to culture a heterogeneous population of cells while narrowing the window of examination.
The three-dimensional nature of this system has the advantage of allowing a more physiological mesenchymal transformation than traditional two-dimensional EndMT assays. An endothelial cell which has undergone full mesenchymal transformation will not only change morphology and phenotype, but will invade its underlying substrate and develop complex mechanisms of interaction with its three-dimensional extracellular environment. 22 This system allows full invasion of VEC undergoing EndMT into the physiologically relevant environment of collagen hydrogel.
Allowing matrix invasion makes assessment of traits such as matrix interactions and matrix metalloproteinase expression in transformed and non-transformed VEC possible. The results of this study suggest that VEC cultured on the membrane undergoing TNFa-stimulated EndMT invade the matrix to the same extent as VEC cultured directly on the hydrogel 24 (data not shown), despite the difference in stiffness between each surface. An assessment of the effect of the difference in stiffness between membrane and hydrogel could be easily conducted using membranes of different materials with different mechanical properties. The membrane used here can be adjusted via modulation of pore size, hydrogel composition, and membrane coating substrate.
Beyond developing a system for assessment of transforming and non-transforming VEC undergoing EndMT, we have evaluated the dynamics of this process in the initial response of VEC to TNFa. Our results show that inflammatory EndMT is a complex phenomenon with the potential to contribute to various elements of early valve disease. Mesenchymal transformation could contribute to a fraction of the endothelial denudation observed in diseased valves, linking inflammatory activation of the endothelium 13, 17 to endothelial loss during the calcification stage. 15 Unraveling the time dynamics of EndMT in the valve is key in understanding the role of certain biological actors known to play complex parts in the progression of valve disease. For example, TGF-b is known to have both protective 23 and detrimental effects 31 in the aortic valve. These complex and seemingly opposing responses can be elucidated via this membrane system, which separates VEC as they transform or resist transformation, elucidating the time-dependency of each event. Further complexity could be assessed via addition of co-cultured valvular interstitial cells to the hydrogel component. Finally, the system can be used to screen anti-EndMT therapies (such as in the context of cancer or fibrosis) 11, 19 in a stage-dependent manner.
The fate of adult VEC undergoing EndMT is unclear. This study provides initial evidence that T-VEC may be participants in some of the early mechanisms of AVD, through increased expression of MMP-9, TGF-b1, Notch1, and BMP-4, as well as via collagen remodeling. MMP-9 is expressed in stenotic but not healthy aortic valves, 9 linking increased MMP-9 and T-VEC collagen remodeling to the changes in extracellular matrix organization observed in early valve disease. We note that remodeling of a collagen hydrogel is not the same as T-VEC affecting the complex ECM composition of a native valve, but their aggressive invasive phenotype and distinct effects on collagen fiber alignment suggest that they have increased ability to affect their extracellular environment. TGF-b1 is known to be regulated by TNFa and is implicated in accelerating calcification of aortic VIC. 21, 25 T-VEC in this study had increased TGF-b1 mRNA, whereas NT-VEC had levels comparable to quiescent VIC. T-VEC may contribute to levels of TGF-b1 in the diseased aortic valve, accelerating calcification of native VIC. Notch1 initiates EndMT in the developing valve 8 and in postnatal aortic VEC.
33
Notch1 was increased in T-VEC, agreeing with a link to valve EndMT. Interestingly, levels of Notch1 in NT-VEC were comparable to VIC controls and lower than control VEC, suggesting that they may have a decreased EndMT potential or a native predisposition against EndMT. Future studies are needed to assess whether Notch1 levels in T-VEC could be repressed over longer time-scales, as has been shown in animal models of aortic valve calcification and in humans.
12
BMP-4 mediates endothelial inflammatory activation, 30 promotes vascular calcification, 5 and initiates EndMT in valvulogenesis. 20 BMP-4 antagonists are repressed in CAVD.
2 BMP-4 was decreased in NT-VEC, agreeing with a quiescent or protective role for these cells in valve disease. BMP-4 was increased in T-VEC, which could contribute both to a continued EndMT-activation paradigm and to acceleration of calcification. Sustained activation of inflammatory adhesion molecules ICAM-1 and VCAM-1 in NT-VEC suggests that the population of VEC that resists transformation under TNFa treatment is able to maintain an inflammatory phenotype while not undergoing EndMT. This result, coupled with the sustained endothelial phenotype of these cells as evidenced by maintaining control levels of VE-cadherin and endothelial nitric oxide synthase, suggest that this population of cells may possess a distinct molecular signature which protects against some of the detrimental effects of inflammation.
This study is an initial investigation of the differences in aortic valve endothelial response to TNFa, specifically regarding the EndMT response mechanism. The in vitro nature of the study makes it well suited for separating distinct cell populations and characterizing their time-dependent response to treatment. We recognize that TNFa treatment represents one facet of early AVD and the EndMT response is a single component of a complex pathological phenomenon. In addition, our method of harvesting cells from across the entire surface of the porcine aortic valve, rather than in a side-specific manner, does offer continuing avenues of exploration in terms of identifying whether transforming VEC come preferentially from certain regions of the aortic valve surface or whether tendency to transform is effected from extracellular phenomenon such as shear stress or strain. These elements could easily be incorporated into the system described in this study, with the same benefits of ability to separate distinct populations and allow fully three-dimensional invasion and matrix interactions. Overall, the threedimensional nature of the system, the molecular signatures identified between transforming and nontransforming populations, and the amenability of the technique to increasing levels of complexity across time, cell type, and endpoint analysis lays an important foundation for understanding the role of EndMT in valve disease progression.
CONCLUSION
In the present study, we have designed a system that allows for highly specified characterization of EndMT dynamics. We have built upon previous studies to validate the ability of the system to allow healthy endothelial cells treated with TNFa to undergo the full phenotypic shift characteristic of EndMT, including repression of endothelial proteins, upregulation of mesenchymal proteins, and invasion into a three-dimensional collagen hydrogel environment. We have shown that the subset of VEC which undergo TNFa-EndMT may have unique abilities to contribute to the earliest stages of AVD via collagen remodeling and increased MMP-9, TGF-b1, Notch1, and BMP-4 expression. The subset of VEC which resists TNFa-EndMT is shown to express inflammatory adhesion proteins and retain endothelial characteristics such as VE-cadherin, CD31, and endothelial nitric oxide synthase expression. The results of this study provide an important baseline for isolation and characterization of VEC that have undergone postnatal End-MT. We have designed a system which can be used for investigation of EndMT dynamics across physiological contexts, demonstrated that there exists a subpopulation of VEC with resistance to TNFa-EndMT, and shown for the first time that transformed VEC have a phenotype which suggests they could contribute to advanced AVD.
